Molecular Biology of Chronic Thromboembolic Pulmonary Hypertension

Semin Thorac Cardiovasc Surg. Fall 2006;18(3):265-76. doi: 10.1053/j.semtcvs.2006.09.004.


Recent efforts have seen major advances in elucidating the mechanisms underlying pulmonary arterial hypertension. However, chronic thromboembolic pulmonary hypertension (CTEPH) often has been excluded from these studies. Consequently, whereas the clinical, radiographic, and hemodynamic characteristics of CTEPH have been well described, there remains a deficit in our understanding of the cellular, molecular, and genetic mechanisms underlying CTEPH. Furthermore, although prior venous thromboembolism may act as the inciting event, it is still unclear what predisposes some patients to develop CTEPH. CTEPH has two major pathogenic components. The first is the primary obstruction of central pulmonary arteries by accumulation of thrombotic material. The second is characterized by severe pulmonary vascular remodeling, similar to that seen in idiopathic pulmonary arterial hypertension. Other articles in this series describe the pathological, surgical, and therapeutic aspects of CTEPH. Here, we review the potential molecular and cellular mechanisms that may contribute to the pathogenesis of CTEPH.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Chronic Disease
  • Disease Susceptibility
  • Endothelium / physiopathology
  • Humans
  • Hypertension, Pulmonary / genetics
  • Hypertension, Pulmonary / physiopathology*
  • Molecular Biology*
  • Platelet Aggregation
  • Pulmonary Embolism / genetics
  • Pulmonary Embolism / physiopathology*